Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With 9 mg Budesonide or 3 g Mesalazine in Patients With Active Ulcerative Colitis.
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Budesonide; Mesalazine
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Dr Falk Pharma
- 10 Nov 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 10 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Oct 2009 New trial record.